IL241326B - Allogenic cell containing compositions and uses thereof in immunotherapy - Google Patents

Allogenic cell containing compositions and uses thereof in immunotherapy

Info

Publication number
IL241326B
IL241326B IL241326A IL24132615A IL241326B IL 241326 B IL241326 B IL 241326B IL 241326 A IL241326 A IL 241326A IL 24132615 A IL24132615 A IL 24132615A IL 241326 B IL241326 B IL 241326B
Authority
IL
Israel
Prior art keywords
immunotherapy
cell containing
containing compositions
allogenic cell
allogenic
Prior art date
Application number
IL241326A
Other languages
Hebrew (he)
Other versions
IL241326A0 (en
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/796,171 external-priority patent/US9320794B2/en
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of IL241326A0 publication Critical patent/IL241326A0/en
Publication of IL241326B publication Critical patent/IL241326B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL241326A 2013-03-12 2015-09-08 Allogenic cell containing compositions and uses thereof in immunotherapy IL241326B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/796,171 US9320794B2 (en) 2006-11-13 2013-03-12 Ablative immunotherapy
PCT/US2014/022287 WO2014164396A1 (en) 2013-03-12 2014-03-10 Ablative immunotherapy

Publications (2)

Publication Number Publication Date
IL241326A0 IL241326A0 (en) 2015-11-30
IL241326B true IL241326B (en) 2021-05-31

Family

ID=51658863

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241326A IL241326B (en) 2013-03-12 2015-09-08 Allogenic cell containing compositions and uses thereof in immunotherapy

Country Status (11)

Country Link
EP (1) EP2970910A4 (en)
JP (1) JP6538647B2 (en)
KR (1) KR102265276B1 (en)
CN (2) CN106581673A (en)
AU (2) AU2014249374A1 (en)
BR (1) BR112015022974A8 (en)
CA (1) CA2904853A1 (en)
IL (1) IL241326B (en)
PH (1) PH12015502086A1 (en)
SG (2) SG10201707446PA (en)
WO (1) WO2014164396A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151309B (en) * 2018-02-14 2022-02-15 上海美杰医疗科技有限公司 Preoperative planning method and equipment for multi-modal ablation therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CN1806849A (en) * 2005-01-19 2006-07-26 上海三维生物技术有限公司 Method of treating tumors
US20080112963A1 (en) * 2006-11-13 2008-05-15 Immunovative Therapies, Ltd. Ablative immunotherapy
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2009095033A1 (en) * 2008-01-31 2009-08-06 Agirx Limited Vaccine compositons

Also Published As

Publication number Publication date
SG10201707446PA (en) 2017-10-30
BR112015022974A2 (en) 2017-07-18
CN105102613A (en) 2015-11-25
EP2970910A4 (en) 2016-11-16
CN106581673A (en) 2017-04-26
IL241326A0 (en) 2015-11-30
PH12015502086A1 (en) 2016-01-18
KR102265276B1 (en) 2021-06-16
KR20150138234A (en) 2015-12-09
BR112015022974A8 (en) 2019-11-26
AU2014249374A1 (en) 2015-09-24
CA2904853A1 (en) 2014-10-09
WO2014164396A1 (en) 2014-10-09
EP2970910A1 (en) 2016-01-20
JP2016518319A (en) 2016-06-23
AU2020201309A1 (en) 2020-03-12
JP6538647B2 (en) 2019-07-03
SG11201507350WA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HK1211620A1 (en) Natural killer cells and uses thereof
IL242273B (en) Methods and compositions for enhancing cd4+ regulatory t cells
SG10201610915XA (en) Methods and compositions for natural killer cells
GB201622354D0 (en) SC-� Cells and Compositions and methods for generating the same
GB201321693D0 (en) Composition and uses thereof
EP2968107A4 (en) Cosmetic compositions and uses thereof
EP2854530A4 (en) Compositions and methods for -glucan immunotherapy
HK1206970A1 (en) Antigenic compositions and methods
EP3072953A4 (en) Cell culture container and container in which cell culture has been accommodated
EP3007720A4 (en) Compositions comprising gc- macrophage activating factor and uses thereof
SG11201510150VA (en) Immunotherapy composition and use thereof
IL240090B (en) Compositions comprising l-4-chlorokynurenine and uses thereof
HK1222561A1 (en) Compositions and methods for use in oncology
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
HK1210436A1 (en) Novel cell compositions and methods
IL241326B (en) Allogenic cell containing compositions and uses thereof in immunotherapy
IL243091B (en) Compositions and methods for use in oncology
HUE032878T2 (en) Dermo-protective and dermo-balancing composition
GB201210989D0 (en) Composition and device
HK1219292A1 (en) Cd14 cell compositions and methods of using same cd14
GB201320632D0 (en) Electrochemical cells and components thereof
GB201301022D0 (en) Composition and uses thereof
GB201308242D0 (en) Compositions and uses thereof
GB201221083D0 (en) Electrochemical cells and components thereof

Legal Events

Date Code Title Description
FF Patent granted